Solid tumors retain transcriptional programs inherited from their tissue of origin, but the degree of this retention has not been quantified as a continuous metric, nor has its prognostic relevance been evaluated systematically. We developed the Tissue Memory Score (TMS) by projecting tumor bulk RNA-seq onto principal component axes constructed from 2,694 Genotype-Tissue Expression V8 samples across eight healthy tissues, and applied it to 3,900 primary tumors from eight Cancer Genome Atlas cohorts. Nearest-centroid classification recovered tissue identity in six of eight tumor types (80.1%-100.0% accuracy; chance 12.5%; all p < 10−55). The two failures, gastric and endometrial carcinoma, reflected limitations of the reference atlas composition and not loss of tissue memory. Among cohorts passing pre-specified retention and dedifferentiation gates, TMS was independently associated with overall survival in clear cell renal cell carcinoma (ccRCC; multivariable HR = 0.59 per SD; 95% CI 0.46-0.77; p = 6.6 × 10−5) and accounted for 16.3% of explained survival variance by Shapley decomposition. The association held under purity residualization, rank transformation, stage stratification, and progression-free interval as an alternative endpoint. In hepatocellular carcinoma, TMS showed a protective univariable association in the same direction, which did not survive multivariable adjustment and is reported as exploratory. External application to CPTAC-ccRCC yielded a pooled hazard ratio of 0.71 in the same direction (I2 = 0%). Tissue-of-origin transcriptional memory is quantifiable in solid tumors and independently prognostic in ccRCC, but did not extend to the remaining seven cohorts. Broader applicability depends on whether the reference atlas represents the cellular compartment from which a given carcinoma arises.
2 August 2026 in Urologic Oncology: Seminars and Original Investigations
Background: Untargeted proteomics enables quantitative host cell protein (HCP) determination in biotherapeutics, yet no workflow has been validated under ICH Q2(R2) for regulated quality control. Methods: A prospective total-error (TE) validation of label-free ddaPASEF proteomics was performed. A stable isotope-labeled whole-proteome standard was spiked into NISTmAb at seven levels (20–80 ng) and analyzed in four independent assays (198 injections), supporting one-way random-effects ANOVA with Welch–Satterthwaite adjustment. Peptide-level identification error was evaluated by dual entrapment. Results: Empirical false-discovery proportions were below 1% at q = 0.01. Weighted least-squares regression (R2 = 0.993) confirmed stable proportional compression with 81–85% recovery. Repeatability dominated the variance structure (median CV 2.7%); intermediate precision SD ranged from 0.69% to 3.81%. Both 95% β-expectation and 95/95 content tolerance intervals were contained within ±30% at all levels, defining a validated range of 20–80 ng. Abundance-stratified TE profiling revealed concentration-dependent calibration heterogeneity, with stratum-specific intervals within ±35% defining an abundance-aware LLOQ of 3.6 ppm (P95 = 3.87 ppm). Robustness under independent search software (FragPipe v24.0, CCC = 0.998) and cross-platform acquisition (Astral, CCC = 0.980) remained within ±30% limits. Conclusions: This constitutes the first prospective ICH Q2(R2)-aligned validation of untargeted proteomics for HCP quantification, with a transferable statistical framework for high-dimensional analytical methods.